We determined that the Department’s oversight of its drug interdiction efforts did not align with the Office of National Drug Control Policy’s (ONDCP) National Drug Control Strategy. . This occurred because DHS lacks formal oversight roles and responsibilities to ensure its drug interdiction performance activities met both ONDCP and legislative requirements. As a result, DHS could not ensure its drug interdiction efforts met required national drug control outcomes nor accurately assess the impact of the approximately $4.2 billion it spends annually on drug control activities. We made two recommendations that, if implemented, will improve DHS’ drug interdiction efforts. DHS concurred with both recommendations.
Consistent with CDC guidance, most Office of Inspector General employees are currently serving the American people remotely. We are determined to keep interruptions to our operations to a minimum, and we appreciate your patience during this time.
Information and guidance about COVID-19 is available at coronavirus.gov.
- Executive SummaryReport NumberOIG-17-09Issue DateDocument FileDHS AgencyOversight AreaFiscal Year2017